The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 39 results
Sort by date: Descending
Encores: Not included
American Academy of Child and Adolescent Psychiatry
October 14th – 19th 2024
Bipolar Disorder
POSTER
Olanzapine and Samidorphan in Pediatric Patients With Bipolar I Disorder: Pharmacokinetic Results From a Phase 1, Multidose, Open-Label Study
AUTHOR(S)

Melissa DelBello,1 Liming Zhang,2 Ishani Landry,2 David McDonnell,3 Lara Finlayson2

View poster
Bipolar Disorder
European Sleep Research Society
September 24th – 27th 2024
Sleep-wake disorders
POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients With Idiopathic Hypersomnia: An Initial Proof of Concept Phase 1b Study
AUTHOR(S)

Brendon Yee,1 Ron Grunstein,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Shifang Liu,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2
 

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients With Narcolepsy Type 2 An Initial Proof of Concept Phase 1b Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Shifang Liu,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Vibrance-1: Study Design and Methods for a Phase 2, Randomised, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 1
AUTHOR(S)

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Anne Marie Morse,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Vibrance-2: Study Design and Methods for a Phase 2, Randomised, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 2
AUTHOR(S)

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Chad Ruoff,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5

View poster
Sleep-wake disorders
American Diabetes Association
June 21st – 24th 2024
Alcohol Use Disorder
POSTER
Comorbid Alcohol Use Disorder Is Associated With Increased Acute Care Utilization In Patients With Diabetes and Chronic Kidney Disease
AUTHOR(S)

Regina Grebla1, Lauren Strand1, Summera Zhou2, Xin Zhao2, Allison Keshishian3, Monica McClain2, Sandra Springer4

View poster
Alcohol Use Disorder